United States, serotype 19A arose as the most common IPD-causing serotype following widespread use of the 7-valent pneumococcal conjugate vaccine (PCV7) in national immunization programs [5, 6] . A randomized controlled study in the Netherlands demonstrated that an increase in serotype 19A nasopharyngeal acquisition was detected among PCV7 recipients, compared with unvaccinated controls [7] . However, increases in serotype 19A diseases also occurred in countries without PCV7 implementation [8, 9] . Thus, the emergence of 19A likely is due to multiple factors, including the prevalence of 19A carriage, the properties of individual pneumococcal clones, and variations in antibiotic and vaccine use.
In the United States, most serotype 19A disease is due to proliferation of preexisting sequence type (ST) 199 and of a new strain, designated ST320 [5] . Indeed, serotype 19A ST320 is prevalent in many countries [5, 8, 10, 11] . ST320 is a double-locus variant of ST236. ST236, an international Taiwan 19F -14 (ST236) clone with high antibiotic resistance, had spread globally prior to the introduction of PCV7 [12] . Work by Moore et al suggested that the serotype 19A ST320 strain was derived from a capsular switching event that occurred between an international Taiwan 19F -14 (ST236) strain and a serotype 19A strain [5] . In Taiwan, serotype 19A had become, by 2007, one of the common serotypes in children with IPD, despite the low PCV7 vaccination rate [13] . Studies in Taiwan have shown the predominance of ST320 among serotype 19A isolates [14, 15] . In Taiwan and Korea, where PCV7 vaccination rates are low or even absent, the serotype 19A ST320 strain has replaced Taiwan 19F -14 (ST236) as the cause of disease in children [8, 13] . Antibiotic resistance, not PCV7 use, was thought to be the strongest factor overall in serotype 19A ST320 emergence [8] . But, we observe that there are some differences between 19A and 19F in clinical terms. For example, although there are studies that have documented the invasive potential of serotype 19F strains, which can cause pneumonia and empyemas [16] [17] [18] , serotype 19A strains were highly associated with necrotizing pneumonia and the development of bronchopleural fistula [14] -14 (ST236) strain used in the study was recovered from the blood of a child with pneumococcal infection. The serotype 19A ST199 strain used in this study was kindly provided by Professor Donald E. Low (University of Toronto, Canada). The amoxicillin minimum inhibitory concentrations of the 19A ST320, Taiwan 19F -14 (ST236), and serotype 19A ST199 strains were 8, 2, and 0.125 µg/mL, respectively. We used the different antibiotic susceptibilities to differentiate between ST320, ST236, and ST199 in the animal model.
Serotyping of Isolates
Polysaccharide capsule types were determined on the basis of the Quellung test with factor-specific sera (Statens Serum Institut, Copenhagen, Denmark).
Multilocus Sequence Typing
Multilocus sequence typing was performed as described previously [16] . The primers used for polymerase chain reaction (PCR) amplification have been described previously [19] .
Construction of a Serotype 19A ST320 Capsular Polysaccharide Locus (cps) Deletion Mutant
A DNA fragment spanning the dexB locus was amplified by PCR, using chromosomal DNA from the serotype 19A ST320 strain as a template. The fragment was cloned into the pGEM-T Easy vector (Promega); the resulting plasmid was cleaved with PstI, and a cassette encoding spectinomycin resistance was ligated into the PstI site. The resulting construct was cleaved with SacI and then ligated with a DNA fragment containing the aliA locus, which had been amplified by PCR from chromosomal DNA of the serotype 19A ST320 strain. The pGEM:: dexB/spec/aliA plasmid was used to transform the serotype 19A ST320 strain with selection for resistance to spectinomycin and create a serotype 19A ST320 cps deletion mutant. Primers used in the study are listed in Table 1 . (ST236) strains are larger and smoother than that of the 19A ST320 cps deletion mutant, which enabled us to screen for encapsulated strains among the transformants. Once we had identified an isolate with the serotype 19F capsule, we purified DNA from that isolate and used it to transform the serotype 19A ST320 cps deletion mutant into an encapsulated strain again. This backcross transformation procedure was repeated 3 times to construct triple-backcross (ie, 3 × backcross) transformants [20] . The 3 × backcross transformant was expected to have an extremely low probability of carrying any given gene from the original 19F donor, apart from the capsule gene cluster [20, 21] . The amoxicillin minimum inhibitory concentration of the isogenic serotype 19F capsular variant of serotype 19A ST320 (serotype 19F ST320) was 8 µg/mL.
Construction of an

Mouse Challenge
Serotype 19A ST320, its isogenic serotype 19F variant (serotype 19F ST320), and Taiwan 19F -14 (ST236) were grown in THY medium to mid-logarithmic phase (OD 620 , 0.2-0.5) for intranasal and intravenous challenges. The bacterial cultures then were diluted (using phosphate-buffered saline [PBS] ) to the desired cell density (measured in colony-forming units [CFU] per milliliter), using a previously determined standard curve (OD vs actual CFU) generated for pneumococci. The nominal size of the inoculating doses were confirmed by viable counts after plating on blood agar plates.
Animal studies were performed with 3-week-old female BALB/c mice, using groups of 5-10 mice. All experiments were approved by the local ethical committee for animal research. For the sepsis model, intravenous challenge doses of pneumococci were injected directly into the dorsal tail vein. For the colonization and pneumonia model, mice were anesthetized with 20 mg/kg ketamine and infected by intranasal challenge (instillation). At 24 and 48 hours after injection, the animals were euthanized. The trachea was exposed and cannulated for instillation of 500 μL of sterile PBS. The nasal lavage fluid exiting the nares was collected. The lungs were removed, rinsed in PBS, and homogenized. Nasal lavages and lung homogenates were subjected to serial dilution and plated on blood agar to determine the number of viable pneumococci. For the competition experiments, bacteria were combined at 1:1 ratios of CFU. A total of 20 μL (5 × 10 7 CFU of each strain) was used for intranasal challenge, as described previously [22] . After 7 days, mice were killed, and nasal lavages were collected. The recovery of CFU was determined by dilution and plating on blood agar as described above. ST199, recovered organisms were distinguished by replica plating on blood agar containing 4 µg/mL amoxicillin. Briefly, replica plating was performed on agar containing 4 µg/mL amoxicillin to inhibit the ST236 and ST199 strains and allow quantitation of the ST320 colonies. The CFU for the ST320 strains subtracted from the total CFU recovered from plating nasal lavages onto blood agar without amoxicillin gave the CFU for the ST236 and ST199 strains. For competition between serotype 19A ST320 and its isogenic 19F variant (serotype 19F ST320), recovered organisms were distinguished by screening, using the Quellung test with factor-specific sera. The multilocus sequence type was not rechecked. Fifty randomly picked colonies were tested per mouse. A competitive index was calculated on the basis of the ratio of the competing bacterial strains recovered in nasal lavages normalized to the ratio of respective bacteria in the inoculum.
Statistical Analysis
Statistical comparisons of incidence were performed using Poisson distribution with 95% confidence intervals; 95% confidence intervals for which the upper and lower bounds did not include 0 were interpreted as statistically significant. To test for significant differences between groups, the Mann-Whitney U test was used for continuous variables. The mouse competitive index assay was analyzed with a 1-sample, 1-tailed Student t test, using log-transformed competitive indexes to determine were assessed for survival and for bacterial outgrowth over time in the nasopharynx and lungs. At 7 days after instillation, no significant difference was seen in the survival rates (data not shown). After 24 and 48 hours, the 2 strains exhibited similar bacterial outgrowth in the lung (P > .05; Figure 1A and 1B). However, nasal lavages revealed significantly higher densities in mice infected by serotype 19A ST320 ((P = .047 and P = .016 at 24 and 48 hours, respectively; Figure 1C and 1D) To mimic the natural situation in which pneumococci of different serotypes may compete for the same niche and to reduce To assess the role of capsular type on virulence, the competition assay was repeated with the serotype 19A ST320 strain and its isogenic serotype 19F variant (serotype 19F ST320). At 7 days after instillation, the isogenic serotype 19F variant (serotype 19F ST320) was 2-fold less competitive than its parent serotype 19A ST320 strain for colonization of the mouse upper airway (competitive index, 0.47; P = .04; Figure 2B ). Figure 2C ).
Nasopharyngeal Competition Between
Nasopharyngeal Competition Between Serotype 19A ST320 and Serotype 19A ST199
In the United States, ST199 was the predominant clone of serotype 19A prior to the introduction of PCV7, after which ST320 Figure 1 . Intranasal challenge of 3-weeks-old female BALB/c mice with serotype 19A ST320 and Taiwan 19F -14 (ST236) strains separately. A and B, Bacterial counts in the lungs at 24 and 48 hours after challenge. P > .05 at 24 and 48 hours. C and D, Bacterial counts in the nasal lavages at 24 and 48 hours after challenge. P = .047 at 24 hours, and P = .016 at 48 hours.
became more common and, in some areas, the most common 19A clone. Thus, we compared serotype 19A ST320 isolates with serotype 19A ST199 strains in the murine colonization model by means of a competition assay. At 7 days after instillation, the serotype 19A ST320 strain did not significantly outcompete the serotype 19A ST199 strains (competitive index, 2.3; P = .3; Figure 2D ). Serotype 19A ST320 was comparable to serotype 19A ST199 for colonization of the mouse upper airway.
DISCUSSION
During 2008-2011, in a Taiwanese population in which onethird of children received PCV7, the overall rate of IPD among children <5 years did not decrease but significantly increased. The increase of IPD due to serotype 19A was a major contributor to the increase in IPD. Clonal expansion of the serotype 19A ST320 clone resulted in the increase in IPD due to serotype 19A. Taiwan is an epicenter of highly resistant bacteria [23] and was where Shi et al first identified Taiwan 19F -14 (ST236) as a major clone of penicillin-resistant S. pneumoniae [24] . The Taiwan 19F -14 (ST236) clone was presumed to have emerged in the Far East during the 1990s and then to have been disseminated internationally [25, 26] . In our previous studies, the Taiwan 19F -14 (ST236) clone was one of the common strains causing IPD among children [27] and was responsible for the spread of high-level β-lactam resistance in Taiwan [12] . At the time of those reports, serotype 19A was not seen among the isolates associated with disease or elevated antibiotic resistance. However, since 2010, serotype 19A has emerged as the most common type causing IPD under a low rate of PCV7 coverage in Taiwan. Although the complete genome sequence of the serotype 19A ST320 clone has been decoded [11] -14 (ST236) strain in the nasopharynx of mice. Antibiotic stress, such as that resulting from the use of aminoglycosides or fluoroquinolones, can induce genetic transformability in S. pneumoniae, select for resistant clones, and promote the evolution of virulence [28] . It is likely that environmental pressures in Taiwan, including high antibiotic stress [23, 29] , have driven the appearance and spread of the serotype 19A ST320 clone. Even in the absence of PCV7 vaccination, the serotype 19A ST320 clone might circulate and cause pneumococcal disease among children in Taiwan. In the mouse colonization model without antibiotic use, serotype 19A ST320 was not outcompeted by serotype 19A ST199. The result can explain why the ST320 background has been successful in the United States, especially under high-level antimicrobial resistance pressure [5, 30] .
The pneumococci commonly reside on the mucosal surfaces of the upper respiratory tract as asymptomatic colonizers, with transmission occurring from this reservoir of commensal organisms. Colonization is the initial step in the pathogenesis of all pneumococcal disease [31] . Effective colonization by pneumococci would give the species increased access to normally sterile sites, contributing to the species' virulence, pathogenicity, and prevalence in the community. In the present study, we demonstrated that the serotype 19A ST320 strain exhibited effective colonizing ability as compared to its ancestral Taiwan 19F -14 (ST236) strain. The evolution of Taiwan 19F -14 (ST236) to serotype 19A ST320 presumably provided the clone with increased capacity for host colonization. Although serotypes 19A and 19F belong to the same serogroup and have a similarly structured capsular polysaccharide, we found that 19A colonized more effectively than 19F in this study. More importantly, the genetic change from ST236 to ST320 confers a competitive advantage in nasopharyngeal colonization. We are trying to compare the transcriptomes between the 2 strains to identify whether there are differences between 19A ST320 and Taiwan19F-14 (ST236) in some of the attachment proteins that can explain the differences in colonization effectiveness and virulence between them. The remarkable plasticity and heterogeneity of pneumococcal isolates reflect the ability of this species to take up DNA from the environment through natural competence [32] . Genetic exchanges via homologous recombination usually occur between pneumococci or closely related oral streptococci [33] . Thus, clone ST320 may have acquired effective colonization and virulence properties through horizontal gene transfer.
In conclusion, the virulence characteristics of serotype 19A ST320 clone are adaptations that increase the strain's persistence within a host during colonization. In view of these findings, design of a vaccine that prevents S. pneumoniae colonization may be a better way to prevent pneumococcal disease [34] .
Notes
